Broad-spectrum cyclic boronate β-lactamase inhibitors featuring an intramolecular prodrug for oral bioavailability

Bioorganic & Medicinal Chemistry
2022.0

Abstract

Early efforts to broaden the spectrum and potency of cyclic boronic acid β-lactamase inhibitor vaborbactam included a series of 7-membered ring boronates. Exploration of stereoisomers and incorporation of heteroatoms allowed identification of the all-carbon cyclic boronate with substituents trans as the preferred core structure, showing inhibition of Class A and C enzymes. Crystal structures of one analog bound to important β-lactamase enzymes were obtained. When isolated under acidic conditions, these compounds spontaneously formed a neutral cyclic anhydride (intramolecular prodrug) which was shown to have much-improved oral bioavailability (52-69%) compared to the ring-opened carboxylate salt (9%).

Knowledge Graph

Similar Paper

Broad-spectrum cyclic boronate β-lactamase inhibitors featuring an intramolecular prodrug for oral bioavailability
Bioorganic & Medicinal Chemistry 2022.0
Structure-based optimization of cephalothin-analogue boronic acids as β-lactamase inhibitors
Bioorganic & Medicinal Chemistry 2008.0
Discovery of VNRX-7145 (VNRX-5236 Etzadroxil): An Orally Bioavailable β-Lactamase Inhibitor for Enterobacterales Expressing Ambler Class A, C, and D Enzymes
Journal of Medicinal Chemistry 2021.0
Click Chemistry in Lead Optimization of Boronic Acids as β-Lactamase Inhibitors
Journal of Medicinal Chemistry 2015.0
Spirocyclopropyl β-Lactams as Mechanism-Based Inhibitors of Serine β-Lactamases. Synthesis by Rhodium-Catalyzed Cyclopropanation of 6-Diazopenicillanate Sulfone
Journal of Medicinal Chemistry 2003.0
Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections
Journal of Medicinal Chemistry 2020.0
Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases
Journal of Medicinal Chemistry 2015.0
Discovery of 3-aryl substituted benzoxaboroles as broad-spectrum inhibitors of serine- and metallo-β-lactamases
Bioorganic & Medicinal Chemistry Letters 2021.0
Structure-Based Development of (1-(3′-Mercaptopropanamido)methyl)boronic Acid Derived Broad-Spectrum, Dual-Action Inhibitors of Metallo- and Serine-β-lactamases
Journal of Medicinal Chemistry 2019.0
Benzopyranones with retro-amide side chains as (inhibitory) β-lactamase substrates
Bioorganic & Medicinal Chemistry Letters 2004.0